MLTX Reports Sonelokimab Results
MoonLake announces week 52 results of sonelokimab from its phase 3 VELA program in hidradenitis suppurativa
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
MLTX: Reports Phase 3 VELA Results
MoonLake announces Phase 3 VELA program week 52 results showing 67.2% of sonelokimab-treated patients achieving HiSCR75 in moderate-to-severe hidradenitis suppurativa